Enanta Q1 net loss $30.1M; plans to start EDP-235 Phase 1 this month

ENANTA PHARMACEUTICALS INC

2022-Q1 EPS reported -$1.48 revenue$27,648,000

Net loss of $30.1M ($1.48 per diluted share) vs $8.3M loss in prior-year quarter.
Royalty revenue from MAVYRET/MAVIRET was $27.6M, down from $31.7M YoY.
R&D expenses rose to $48.5M from $36.7M due to manufacturing for virology programs.
Cash and marketable securities $347.7M; expects sufficient runway for at least two years.
EDP-235 (oral COVID-19 treatment) Phase 1 dosing begins Feb 2022; RSVP topline data expected Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.